Microorganism for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same

a microorganism and diabetes mellitus technology, applied in the direction of biocide, plant growth regulator, biochemistry apparatus and processes, etc., can solve the problems of imposing a substantial cost on the public as well as on patients, losing control of blood glucose levels, late complications, etc., and achieve the effect of reducing the amount of oligosaccharide absorbed

Inactive Publication Date: 2005-05-26
BIONEER
View PDF4 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0033] Therefore, the object of the present invention is to provide microorganisms capable of living within the intestines and converting oligosaccharides produced by the digestive enzymes into non-digestable polysaccharides, and thereby remarkably reducing the amount of oligosaccharide absorbed into the intestines.

Problems solved by technology

Diabetes mellitus is one of the most widespread chronic diseases in the world, which impose a substantial expense on the public as well as on patients of diabetes mellitus and their families.
Failure to treat NIDDM, resulting in losing control of blood glucose levels, leads to death of patients from diseases such as atherosclerosis, and / or may cause late complications of diabetes, such as retinopathy, nephropathy or neuropathy.
However, diet-exercise therapy alone or even combined with chemotherapy using such compounds fails to control hyperglycemia in some of the diabetes mellitus patients.
Administration of insulin is very expensive and painful to patients, and furthermore, may cause various detrimental results and various complications in patients.
Diet-exercise therapy involves a low-calorie and low-fat diet accompanying aerobic exercise, but this therapy requiring a regular performance is hard to continue until achieving the goal.
Despite of instant effects, a surgery for physically removing body fat has limitations due to the risk and cost involved in a surgical operation and insufficient durability of the effects.
Although sulfonylurea stimulates insulin-secretion from β-cells in the pancreas, it may accompany side effects, such as hypoglycemia resulting from lowering blood glucose levels under normal levels.
However, it suffers from side effects, such as, nausea, vomiting and diarrhea.
It, however, accompanies undersirable inhibition of absorption of fat-soluble vitamin and may also cause breast cancer.
However, dexfenfluororamine and fenfluoroamine have side effects of nerve toxicity and valvular heart disease.
Also, sibutramine has side effects of increasing heart rate and blood pressure.
However, taking a large amount of these may induce diarrhea.
However, such method also involves problems in requiring facility and manpower for the production of dietary fiber with low productivity.
However, such materials also cause severe side effects.
For example, dextran may induce excessive bleeding by delaying a blood coagulation time.
As mentioned above, although there have been various researches and efforts to develop drugs for treatment or prevention of obesity and diabetes mellitus, their results were not satisfactory.
Various chemical substances mentioned above, have been developed for treatment of obesity and diabetes mellitus, but still suffer from various side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microorganism for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same
  • Microorganism for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same
  • Microorganism for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

Selecting of Microorganism which Produces Extracellular Polysaccharide from Samples

[0251] In order to isolate microorganisms which produce dietary fibers, samples were collected from glucose factory sewage and other locations. 10 g of the mixture thus collected were disrupted and suspended in 90 ml of physiological saline solution(0.85% NaCl). The said suspended samples were diluted to 10−2, 10−4, and 10−6 in physiological saline solution. These diluted samples then smeared on MRS agar medium containing 1 mg of cycloheximide per 100 ml medium(1% Peptone, 1% beef extract, 0.5% yeast extract, 2% glucose, 0.1% Tween-80, 0.2% Citric Acid Ammonium, 0.5% Sodium Acetate, 0.01% MgSO4, 0.005% MnSO4, 0.2% Sodium Phosphate pH6.5) and on BSH agar medium(2% glucose, 0.5% Peptone, 0.5% yeast extract, 0.27% Na2HPO4, 0.115% Citric Acid pH 5.0)(Hestirin and Schramm, J. Gen. Microbiol., 11:123,1954) and cultured in 30° C. for 72 hours. Approximately 2,000 colonies were selected and were initially i...

example 2

The Morphological Determination and Characteristics of the Selected BC-Y009 and BC-Y058

[0253] Microorganisms which show high polysaccharide productivity selected from the Example 1 were BC-YO09, BC-Y002, BC-Y015, BC-Y026, BC-Y058, BC-Y112, BC-Y130, and BC-Y201. Upon observing partial DNA sequences, BC-YO09, BC-Y002, BC-Y015 and BC-Y026 were microorganisms of Lactobacillus genus, and BC-Y058, BC-Y112, BC-Y130 and BC-Y201 were microorganisms of Acetobacter genus.

[0254] Among these bacteria, BC-Y009 and BC-Y058 which show high polysaccharide productivity were inoculated in MRS and BSH liquid mediums at 30° C. for 72 hours and cultured in suspension. Cultured mediums were centrifuged at 6,000 rpm in 4° C. to obtain microorganisms and the nucleic acids thereof were isolated by means of using the CTAB / NaCl method. By using 16 s rRNA consensus primer, 16 s rRNA was amplified by means of PCR method, and the sequence thus obtained, was determined. BLAST analysis (NCBI, USA) on the sequenc...

example 3

The Degree of Decomposition of Extracellular Polysacchride (Dietary Fiber) bV Intestinal Digestive Enzymes

[0260] In order to determine whether or not dietary fiber produced by said microorganisms is decomposed by intestinal digestive enzyme, 1 g of porcine pancreatin that shows the activity of 3×U.S.Pharmacopia (manufactured by Sigma) and comprises amylase, lipase, protease and nuclease, was suspended in buffer solution (pH7.5) of 1 g of dried dietary fiber. This suspension was incubated for 7 days at 40° C. and the suspension was collected once a day and the glucose therein was analyzed quantitatively by using DNS(3,5-dinitrosalicylic acid). The result thereof showed that dietary fibers has never been decomposed at all.

[0261] Therefore, it was confirmed that the dietary fibers produced by the microorganisms of the present invention do not decompose within the intestine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

Description

FIELD OF THE INVENTION [0001] The present invention relates to microorganisms for preventing or treating obesity or diabetes mellitus, which are capable of reducing an amount of monosaccharides or disaccharides that can be absorbed into the intestine by converting those mono or disaccharides into polymeric materials that cannot be absorbed in the intestines. The present invention also relates to use of the microorganisms for preventing or treating obesity or diabetes mellitus and a pharmaceutical composition containing the microorganisms. BACKGROUND OF THE INVENTION [0002] Obesity is well known as a chronic disease caused by various factors whose origins have not yet been clearly discovered. It is understood that obesity induces hypertension, diabetes mellitus, coronary heart disease, gall bladder disease, osteoarthritis, sleep apnea, respiratory disorder, endomerial, prostate, breast and colon cancer and the like. [0003] According to the NIH Report (THE EVIDENCE REPORT: Clinical Gu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N1/20A61K35/74A61K35/741A61K35/744A61K35/747A61P3/04A61P3/10C12R1/02C12R1/225
CPCA61K35/74Y10S435/823A61K35/744A61K35/745A61K35/747C12R1/02C12R1/225A61K35/742Y10S435/853A61K2300/00A61P3/04A61P3/10C12N1/205C12R2001/02C12R2001/225
Inventor PARK, HAN OHBANG, YOUNG BAEJOUNG, HEA JUNGKIM, BONG CHEOLKIM, HANG RAE
Owner BIONEER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap